Wendy Rubinstein, MD, PhD, FACP, FACMG is Deputy Medical Director of CancerLinQ. She represents ASCO and CancerLinQ in external collaborations, provides genomics expertise, and organizes CancerLinQ’s scholarly work. Dr. Rubinstein directed academic cancer genetics programs for 15 years at three NCI-designated Comprehensive Cancer Centers. Prior to joining CancerLinQ in 2017, Dr. Rubinstein was Senior Scientist at the National Institutes of Health, where she launched and directed the NIH Genetic Testing Registry and served as Chief of Medical Genetics and Human Variation at NCBI, hosting flagship information resources including ClinVar, dbSNP, dbGaP, GeneReviews, and GTR. She was a representative to the NIH-FDA-CMS Trilateral Genomic Medicine Workgroup and FDA-NIH Interagency Task Force on Laboratory Developed Tests, and received the NIH Director’s Award from Dr. Francis Collins. An NIH Medical Scientist Training Program scholarship awardee, Dr. Rubinstein earned her MD and PhD degrees at the Mount Sinai School of Medicine. She holds dual board certification in clinical genetics and clinical molecular genetics. Dr. Rubinstein has authored publications on gene discovery (SDHD), variant interpretation, computerized familial risk assessment, pharmacogenomics, genetic modifiers, clinical practice guidelines, and health information technology.
Deputy Medical Director